Women who are being treated for breast cancer are often prohibited from using traditional hormone replacement therapy because breast cancer can be sensitive to estrogen, the predominant female hormone.
Moreover, custom-built apps for therapy and science education are cropping up, with the existing prototype utilizing a trio of force-sensitive resistors that measure pressure and convert it into a signal that instructs the tablet.
After a year on therapy, 54% to 57% of patients on Tasigna had no signs of leukemia using the most sensitive test vs. just 30% of those who were on Gleevec.